# Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

> **NCT00217412** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Childhood Acute Promyelocytic Leukemia (M3)
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Burkitt Lymphoma
- Childhood Chronic Myelogenous Leukemia
- Childhood Diffuse Large Cell Lymphoma
- Childhood Immunoblastic Large Cell Lymphoma
- Juvenile Myelomonocytic Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Childhood Grade III Lymphomatoid Granulomatosis
- Recurrent Childhood Large Cell Lymphoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Small Noncleaved Cell Lymphoma
- Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Recurrent Neuroblastoma
- Recurrent/Refractory Childhood Hodgkin Lymphoma
- Relapsing Chronic Myelogenous Leukemia
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** vorinostat
- **DRUG:** isotretinoin

## Key facts

- **NCT ID:** NCT00217412
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2014-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217412, "Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00217412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*